Who Will Be The First To Get A Psychedelic Drug Through The FDA To Commercialization?Psyched Wellness Is Laser Focused On Bringing Truly Differentiated Mushroom Products To MarketAtai Life Sciences: The Next Unicorn Of The Psychedelics SectorATAI Life Sciences Announces Closing of $125 Million Series C Financing RoundRritual Mushrooms Is Pioneering The Future Of Functional FoodsMindMed’s Drug Delivery Business Is One That Psychedelic Sector Investors Need To Be WatchingPure Extracts Technologies Corporate UpdateNova Mentis Life Science Announces Receipt of Pilz Shareholder ApprovalField Trip Health Ltd. Announces Expansion to The Netherlands and Launch of Proprietary Truffle ProgramPsyched Wellness Ltd. Announces Insider Buying and Option Grant to Professor NuttMindMed Receives Approval of Protocol Design to Evaluate Microdoses of LSD For Adult ADHD In Phase 2a Clinical Trial froTryp Appoints Dr. Jim Gilligan, PhD, MBIS, as President and Chief Scientific OfficerHavn Life Announces Launch of a Range of Natural Health ProductsCybin Corp. Will Make Its Debut Today On The NEO Under The Symbol “CYBN”Tryp Therapeutics Has “The Right Stuff” To Bring Psychedelic Therapies Through To CommercializationMindset Pharma Closes Ontario Brain Institute Funding and Announces Private Placement OfferingNuminus Wellness Is Executing Flawlessly On Their B2B Strategy via Numinus BiosciencesEntheon Biomedical Corp. (formerly MPV Exploration Inc.) Announces Completion of Amalgamation and Final Approval from thCybin Completes Reverse Take-Over TransactionThe Psychedelic Sector Is Getting A Major Momentum Boost Post U.S. Election
Back

Mind Cure Is Deploying A “5 Sphere” Strategy To Plant Their Flag In The Psychedelics Sector

Oct 1, 2020 • 7:00 AM EDT
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

During the last quarter, we have seen a substantial increase in the number of companies that are focused on the psychedelic therapy market and this is a trend that are closely following.

Earlier this month, we learned about Mind Cure (MCUR.CN) which is an emerging play on the psychedelic therapy market and is focused on discovering new methods to treat people who are suffering from a mental health illness. The mental health and wellness company is working to identify and develop products that ease suffering, increase productivity, and enhance mental health.

One of the reasons we started to follow Mind Cure is related to the team that started the business. Mind Cure is led by a leadership team and advisors that have industry-specific experience in biotech, life sciences, new product discovery, research, technology and entrepreneurship.

Mind Cure represents a multi-faceted growth opportunity and has several avenues to generate revenue. Moonbeam Mushroom brand is the company’s consumer product line of nootropics and we are favorable on the strategy that the management team has for growth.

Mind Cure has a diverse strategic approach that is referred to as 5 spheres. The strategy is a comprehensive approach to investing in products and technology that could provide the business with substantial upside potential. The 5 spheres are:

  • Product Discovery – Investigating product candidates and new psychoactive substances (NPS)
  • Clinical Research Technology – Monitoring psychoactive therapy
  • Nootropic Formulations – Manufacturing and supply of adaptogens
  • Clinical Research – Delivery of psychoactive therapy
  • Formulation and Supply – eGMP and API manufacturing and supply

The 5 Sphere strategy also diversifies the potential impact of the company’s efforts and we are favorable on this aspect of the story. By focusing on a number of indications, Mind Cure has a unique growth profile and we are favorable on how this differentiates the opportunity. Going forward, the name of the game for Mind Cure is execution and we will monitor how the management team is able to drive the story forward and create value for shareholders.

Mind Cure will use evidence based platforms that provide doctors, clinicians and health regulators with data driven research to prove the efficacy of treatments for people who are suffering from mental health diseases. We believe that the mental health market is reaching an inflection point where people are looking for new treatments for debilitating indications and Mind Cure expects to be a beneficiary of this trend.

If you are interested in learning about Mind Cure, please send an email to support@mushroomstocks.com to be added to our distribution and to stay up to date on the opportunity.

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Comments

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link